Melanotan II: Overview

Melanotan II (MT-II) is a cyclic heptapeptide and synthetic analog of alpha-melanocyte stimulating hormone (α-MSH), an endogenous neuropeptide derived from pro-opiomelanocortin (POMC) cleavage. MT-II was developed in the 1980s at the University of Arizona as part of a program to investigate potent, stable melanocortin receptor ligands. It binds with high affinity to melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R — a non-selective profile that has made it a pharmacological tool in multiple research contexts.

The following review presents key findings from published research without therapeutic claims or dosage recommendations.

Study 1: MC1R Agonism and Melanogenesis in Keratinocyte Models

Sawyer et al. (1982) first characterized Melanotan II's potency at melanocortin receptors. Subsequent cell culture studies examined its effects on MC1R-expressing melanocytes — the primary cells responsible for melanin synthesis and skin pigmentation.

Key finding: In MC1R-expressing melanocyte cell lines, MT-II stimulation increased intracellular cAMP levels, activated MITF (microphthalmia-associated transcription factor), and upregulated tyrosinase expression — the rate-limiting enzyme in the melanogenesis pathway.

Key observations included:

  • Dose-dependent increase in melanin synthesis in MC1R+ cell cultures
  • Activation of cAMP/PKA signaling cascade downstream of MC1R
  • Increased tyrosinase, TRP-1, and TRP-2 gene expression
  • Enhanced melanosome maturation and transfer to keratinocytes in co-culture models
  • Significantly greater potency than endogenous α-MSH at MC1R
In vitro cell culture findings. Melanogenesis in living skin is a complex multi-cellular process; in vitro potency at MC1R does not directly predict in vivo pigmentation outcomes.

Study 2: UV Photoprotection Mechanisms in Melanocyte Studies

Dvorak et al. (1999) and related studies investigated whether MC1R activation-induced melanogenesis could provide measurable photoprotection in experimental models.

Key finding: Increased eumelanin production (the brown/black form vs. pheomelanin's red/yellow form) following MC1R activation was associated with greater UV photon absorption capacity in in vitro models, with eumelanin demonstrating approximately 10× greater UV absorption vs. equivalent pheomelanin concentrations.

Research findings included:

  • Eumelanin:pheomelanin ratio shift toward eumelanin following MC1R activation
  • Eumelanin's superior UV absorption properties well-characterized in photophysical studies
  • Enhanced melanosome distribution to upper epidermal layers in activated vs. control cultures
  • MC1R variants (particularly R151C, R160W, D294H) associated with reduced α-MSH responsiveness in human genetics data

Additional note: MC1R genetic variants that reduce responsiveness to α-MSH are among the strongest genetic risk factors for melanoma, establishing the importance of this pathway in photoprotection research.

Melanocortin Receptor Subtype Pharmacology

MT-II's non-selective binding profile across multiple melanocortin receptor subtypes has made it a research tool for studying MC receptor pharmacology in various tissue contexts.

Receptor Primary Distribution Research Context
MC1R Melanocytes, skin Pigmentation, photoprotection; primary focus of Melanotan II skin research
MC3R Hypothalamus, gut Energy homeostasis and feeding behavior research
MC4R Brain (widespread) Appetite regulation, energy expenditure; extensively studied independently
MC5R Exocrine glands Sebaceous gland, sweat gland function research

Note: MT-II's activity at MC4R has made it a tool compound in neuropharmacology research on energy balance and feeding behavior, independent of its pigmentation effects. This is a distinct research context from its MC1R-mediated skin pigmentation pharmacology.

Molecular Profile

Property Value
Type Cyclic heptapeptide (cyclized via lactam bridge)
Molecular weight 1,024.2 Da
Primary receptor targets MC1R, MC3R, MC4R, MC5R (non-selective)
Relative to endogenous α-MSH Greater receptor potency and longer plasma half-life
Storage Lyophilized: -20°C; Reconstituted: 2–8°C, use within 30 days

Quick Reference Summary

  • Mechanism: Potent non-selective melanocortin receptor agonist (MC1–5R)
  • Primary skin research: MC1R agonism increases eumelanin synthesis via cAMP/MITF/tyrosinase pathway
  • Photoprotection research: Eumelanin UV absorption properties studied in cell models
  • Receptor profile: Multi-receptor binding used as tool compound in multiple research contexts
  • Potency: Substantially greater than endogenous α-MSH at MC1R
  • Use context: Research-grade compound for in vitro and preclinical laboratory use only